ArticleThe breast journal2026
Association of CYP3A5 Genetic Variants With Elevated Breast Cancer Risk: A Case-Control and In Silico Analysis.
Article in The breast journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of CYP3A5 Genetic Variants With Elevated Breast Cancer Risk: A Case-Control and In Silico Analysis.The breast journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytochrome P450 3A5 (CYP3A5) is a key xenobiotic-metabolizing enzyme that also participates in the biotransformation of endogenous substrates. Functional genetic variation within CYP3A5 can alter enzyme activity and may consequently modify individual susceptibility to malignancy. The contribution of CYP3A5 genetic variation to breast cancer risk, as well as its potential relevance to tumor biology, remains inadequately characterized in the Bangladeshi population.
objectiveThe current study investigated the relationship of CYP3A5∗3 (rs776746) polymorphism with the susceptibility of breast cancer and explored its relationship with immune infiltration and survival outcomes.
methodsThe study was conducted as a case-control study including 170 breast cancer patients and 170 age-matched healthy individuals. CYP3A5∗3 (rs776746) genotypes were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Genetic associations were calculated using odds ratios (ORs) with 95% confidence intervals (CIs). Complementary computational analyses evaluated the association of CYP3A5 expression with tumor immune-cell infiltration using TIMER2.0 and examined its prognostic relevance through survival data from TCGA accessed via UALCAN.
resultsCYP3A5∗3 genotype frequencies differed significantly between cases and controls. Compared with the wild-type genotype (∗1/∗1), the heterozygote (∗1/∗3) genotype (OR = 2.57; p = 0.0016), mutant homozygote (∗3/∗3) (OR = 1.78; p = 0.0376), and combined variant genotypes (∗1/∗3 + ∗3/∗3) (OR = 2.11; p = 0.0010) were associated with increased breast cancer risk. The CYP3A5∗3 allele was more prevalent in cases than controls (36% vs. 25%; OR = 1.75; p = 0.0009). In silico analysis showed that CYP3A5 expression was positively correlated with immune-cell infiltration of several immune cells. The elevated expression of CYP3A5 was linked to poorer survival in selected clinical subgroups.
conclusionThe findings indicate that the CYP3A5∗3 polymorphism may contribute to genetic susceptibility to breast cancer among Bangladeshi women. Additionally, CYP3A5 expression shows a relationship with immune infiltration and may have subgroup-specific prognostic relevance in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.